Cleared Traditional

CAPILLARYS IMMUNOTYPING, MODEL 2100

K082085 · Sebia · Immunology
Apr 2009
Decision
268d
Days
Class 2
Risk

About This 510(k) Submission

K082085 is an FDA 510(k) clearance for the CAPILLARYS IMMUNOTYPING, MODEL 2100, a Immunoelectrophoretic, Immunoglobulins, (g, A, M) (Class II — Special Controls, product code CFF), submitted by Sebia (Norcross, US). The FDA issued a Cleared decision on April 17, 2009, 268 days after receiving the submission on July 23, 2008. This device falls under the Immunology review panel. Regulated under 21 CFR 866.5510.

Submission Details

510(k) Number K082085 FDA.gov
FDA Decision Cleared SESE
Date Received July 23, 2008
Decision Date April 17, 2009
Days to Decision 268 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement

Device Classification

Product Code CFF — Immunoelectrophoretic, Immunoglobulins, (g, A, M)
Device Class Class II — Special Controls
CFR Regulation 21 CFR 866.5510

Similar Devices — CFF Immunoelectrophoretic, Immunoglobulins, (g, A, M)

All 28
HYDRASHIFT 2/4 isatuximab
K203184 · Sebia · Nov 2021
CAPI 3 Immunotyping, Capillarys 3 Tera
K192095 · Sebia · Nov 2019
HYDRASHIFT 2/4 daratumumab
K190851 · Sebia · May 2019
HYDRASHIFT 2/4 daratumumab, daratumumab Control
K172195 · Sebia · Jan 2018
CAPI 3 IMMUNOTYPING, CAPILLARYS 3 TERA, IT/IF CONTROL
K161928 · Sebia · Dec 2016
MINICAP Immunotyping using the MINICAP and the MINICAP FLEX-PIERCING
K143483 · Sebia · Jan 2015